ClinicalTrials.gg
CompletedNCT02230228Updated Apr 27, 2025

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

A Phase 1 interventional study of ALK-001 (No generic name) in Stargardt Disease, Age-related Macular Degeneration and Other Retinal Dystrophies, sponsored by Alkeus Pharmaceuticals, Inc.. Completed. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Alkeus Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2014, 12 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
21 Years to 70 Years
Sex
All
01

Study summary

This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.

02

Conditions studied

  • Stargardt Disease
  • Age-related Macular Degeneration
  • Other Retinal Dystrophies
03

In context

Stargardt Disease

66 studies on the registry are indexed under Stargardt Disease; 25 are open to participants now.

This study's enrollment of 40 is above the median of 30 across 43 interventional studies indexed under Stargardt Disease.

Browse Stargardt Disease studies →

Lead sponsor

Alkeus Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria

  • Adult between 21 and 70 years old (inclusive)
  • Healthy subject, as judged by investigator
  • Subject is able and willing to comply with study requirements (study medication compliance, schedule of follow-up visits)
  • Subject has provided to participate
  • If female, subject uses a medically accepted method and agrees to use such a method for entire clinical trial period

Main Exclusion Criteria:

  • Subject has taken disallowed items during the past 30 days
  • Female with a positive urine pregnancy test at screening
  • Lactating woman
  • Subject has participated in any clinical study involving an drug, biologic or device, during the past 30 days
  • History or current evidence of gastrointestinal malabsorption
  • Subject has any other medical condition, which in the opinion of the investigator, is likely to prevent compliance with protocol and/or interfere with successful collection of study
  • Subject has, in the opinion of investigator, laboratory result(s), positive drug or alcohol screening, or , which makes subject unsuitable for participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ALK-001 capsules

    Drug: ALK-001 (No generic name)

Interventions

  • Daily, oral administration of ALK-001 capsules.

    Also known as: C20-D3-Retinyl Acetate, C20 Deuterated vitamin A

06

What researchers measure

Primary outcomes

  1. Safety of 4-week daily dosing of ALK-001 in healthy adults.

    Safety evaluations combine: adverse events (AE), laboratory testing (hematology and biochemistry panels), 12-lead electrocardiograms (ECGs), vital signs, physical examination, and visual function (visual acuity and a self-reported questionnaire).

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Sep 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2014
First posted
Sep 3, 2014
Start
Apr 2014
Primary completionActual
Sep 2014
CompletionActual
Feb 2015
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02230228
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Sep 3, 2014
Start date
Apr 2014
Primary completion
Sep 2014
Completion
Feb 2015
Last update
Apr 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gildeuretinol acetate

Start the discussion